Disease · MONDO_0005367
heroin dependence
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. heroin dependence. Diseases, record MONDO_0005367. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005367
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs16
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BUPRENORPHINE | CHEMBL511142 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| METHADONE | CHEMBL651 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| NALOXONE | CHEMBL80 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NALTREXONE | CHEMBL19019 | Small molecule | Phase 2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| DIACETYLMORPHINE | CHEMBL459324 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| DIMEPHEPTANOL | CHEMBL368591 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| FENTANYL | CHEMBL596 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GUANFACINE | CHEMBL862 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HYDROCORTISONE | CHEMBL389621 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEVOMETHADYL ACETATE | CHEMBL1514 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 16
See all 16 drugsTargets8
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| OPRM1 | Mu-type opioid receptor | 11 | Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 3 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| OPRK1 | Kappa-type opioid receptor | 3 | Kappa opioid receptor agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 3 | https://conductscience.org/library/genes/4986 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| OPRD1 | Opioid receptors; mu/kappa/delta | 2 | Opioid receptors; mu/kappa/delta antagonist | Phase 3 | https://conductscience.org/library/genes/4985 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/152 | Drugs and targets |
| TACR1 | Substance-P receptor | 1 | Neurokinin 1 receptor antagonist | Phase 1 | https://conductscience.org/library/genes/6869 | Drugs and targets |
Trials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00574067 | Buprenorphine for Prisoners | Phase 3 | 213 | 2016-04-11 | Heroin Addiction | BUPRENORPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT00378079 | Methadone Maintenance for Prisoners | Phase 3 | 211 | 2014-04-03 | Heroin Addiction | METHADONE | Its record names the disease | ClinicalTrials.gov |
| NCT03711318 | Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals | Phase 3 | 8 | 2022-12-22 | Heroin Dependence | BUPRENORPHINE, NALOXONE | Its record names the disease | ClinicalTrials.gov |
| NCT01580163 | Efficacy Evaluation of Traditional Chinese Medicine JITAI Combined Comprehensive Model Among Heroin Addicts After Detoxification | Not applicable | 554 | Heroin Addiction | METHADONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00142948 | Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts | Phase 2 | 301 | Heroin Dependence | GUANFACINE, NALTREXONE | Its record names the disease | ClinicalTrials.gov | |
| NCT01144390 | Effect Study of Optimized Intervention to Heroin Addicts | Not applicable | 240 | Heroin Dependence | METHADONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00383045 | HIV Risk Reduction and Drug Abuse Treatment in Malaysia | Phase 2 | 180 | Opiate Dependence | BUPRENORPHINE, NALTREXONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00292110 | Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management | Phase 1 | 140 | Opiate-Related Disorders, Cocaine-Related Disorders | METHADONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00332228 | Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence | Phase 2 | 125 | Opiate Dependence | NALTREXONE | Its record names the disease | ClinicalTrials.gov | |
| NCT00726960 | Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers | Phase 1 | 60 | Opioid-Related Disorders, Heroin Dependence, Substance-Related Disorders | APREPITANT | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials14
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005367
GET https://conductscience.org/api/diseases/v1/MONDO_0005367/drugs